SehaMed Global Ltd (“SehaMed”), the Bristol based MedTech platform connecting manufacturers, distributors, and hospitals worldwide, today announced a strategic distribution agreement with New Day Diagnostics, LLC (“New Day Diagnostics”) of Knoxville, Tennessee, to bring ColoHealth™, the first FDA approved blood test for early detection of colorectal cancer, to populations across Saudi Arabia, the United Arab Emirates, and beyond.
Under the terms of the agreement, SehaMed will leverage its platform and network of qualified distributors across the Gulf Cooperation Council (GCC) to introduce ColoHealth. New Day Diagnostics’ Vice President, Rick Jones, commented, “Partnering with SehaMed accelerates our mission to make early CRC screening accessible globally. The Middle East represents a vital region where innovative, non-invasive diagnostics can transform patient outcomes.”
Anne Hegmann-Weston, Director at SehaMed, added, “We are excited to collaborate with New Day Diagnostics to offer ColoHealth to clinicians and patients in Saudi Arabia, UAE, and neighbouring markets. This agreement underscores SehaMed’s commitment to improving patient care by connecting groundbreaking US diagnostics with distributors and healthcare providers in the Middle East.”